Association Between F-SIRI and Adverse Prognosis in Patients With Chronic Heart Failure

High plasma fibrinogen and systemic inflammation response index (F-SIRI) has been proposed as a novel prognostic factor in resectable gastric cancer. However, available data on the prognostic value of F-SIRI in chronic heart failure (CHF) patients is limited. We aimed to conduct a retrospective cohort study exploring the correlation between F-SIRI and prognosis in CHF individuals.

We consecutively enrolled 1589 hospitalized patients (aged 66 ± 8 years, 32.9% women) with CHF from January 1, 2019 to August 31, 2022 in this single-center retrospective study. SIRI was calculated with the formula (monocyte count*neutrophil count/lymphocyte count). The primary endpoints encompassed all-cause death, the major adverse cardiac and cerebral events (MACCEs) and cardiovascular death. The association between F-SIRI and the risk of developing adverse outcomes were explored using four multivariate-adjusted Cox proportional hazard models.

During a median follow-up of 687 days, 207 all-cause deaths, 462 MACCEs and 136 cardiovascular deaths were recorded. After adjusting for potential confounding factors, only risk of all-cause death remained significantly associated with higher levels of F-SIRI. The hazard ratios (HRs) for the highest F-SIRI group (F-SIRI = 2) versus the lowest F-SIRI group (F-SIRI = 0) were 2.37 (95% confidence interval [CI], 1.46-3.83; p < 0.001) for all-cause death. The addition of F-SIRI could increase the prognostic ability for all-cause death on the basis of traditional risk factors.

F-SIRI is a significant predictor of all-cause death but has limited predictive value for MACCEs and cardiovascular death in CHF patients.